Pharmacoeconomics and Health Outcomes: Driving Formulary Access and Reimbursement

Table of Contents

Charts and Graphics

EXECUTIVE SUMMARY

• Figure E.1: Effectiveness Ratings of Pharmacoeconomics/Health Outcomes Groups
• Figure E.2: Pharmacoeconomics/Health Outcomes 2006 Department Budgets
• Figure E.3: Allocation of Pharmacoeconomics/Health Outcomes Departments'

Time Resources

• Figure E.4: Allocation of Pharmacoeconomics/Health Outcomes Departments'

Monetary Resources

• Figure E.5: Preclinical Maximum/Minimum Brand-Level Spending
• Figure E.6: Phase I Maximum/Minimum Brand-Level Spending
• Figure E.7: Phase II Maximum/Minimum Brand-Level Spending

COMPANY 1

• Figure 1.1: Company 1: Background
• Figure 1.2: Company 1: Structure Details
• Figure 1.3: Company 1: Pharmacoeconomics Staffing
• Figure 1.4: Company 1: Budget for 2006
• Figure 1.5: Company 1: Pharmacoeconomics/Health Outcomes Funding
• Figure 1.6: Company 1: Outsourcing
• Figure 1.7: Company 1: Brand-Level Phase-to-Phase Minimum Spending
• Figure 1.8: Company 1: Brand-Level Phase-to-Phase Maximum Spending
• Figure 1.9: Company 1: Time Resource Allocation
• Figure 1.10: Company 1: Monetary Resource Allocation
• Figure 1.11: Company 1: Performance Rating/Top Challenges

COMPANY 2

• Figure 2.1: Company 2: Background
• Figure 2.2: Company 2: Structure Details
• Figure 2.3: Company 2: Structure
• Figure 2.4: Company 2: Department Staffing
• Figure 2.5: Company 2: Budget for 2006
• Figure 2.6: Company 2: Pharmacoeconomics/Health Outcomes Funding
• Figure 2.7: Company 2: Outsourcing
• Figure 2.8: Company 2: Brand-Level Phase-to-Phase Minimum Spending
• Figure 2.9: Company 2: Brand-Level Phase-to-Phase Maximum Spending
• Figure 2.10: Company 2: Time Resource Allocation
• Figure 2.11: Company 2: Monetary Resource Allocation
• Figure 2.12: Company 2: Performance Rating/Top Challenges

COMPANY 3

• Figure 3.1: Company 3: Background
• Figure 3.2: Company 3: Structure Details
• Figure 3.3: Company 3: Structure
• Figure 3.4: Company 3: Department Staffing
• Figure 3.5: Company 3: Budget for 2006
• Figure 3.6: Company 3: Pharmacoeconomics/Health Outcomes Funding
• Figure 3.7: Company 3: Outsourcing
• Figure 3.8: Company 3: Brand-Level Phase-to-Phase Minimum Spending
• Figure 3.9: Company 3: Brand-Level Phase-to-Phase Maximum Spending
• Figure 3.10: Company 3: Time Resource Allocation
• Figure 3.11: Company 3: Monetary Resource Allocation
• Figure 3.12: Company 3: Performance Rating/Top Challenges

COMPANY 4

• Figure 4.1: Company 4: Background
• Figure 4.2: Company 4: Structure Details
• Figure 4.3: Company 4: Department Structure
• Figure 4.4: Company 4: Department Staffing
• Figure 4.5: Company 4: Budget for 2006
• Figure 4.6: Company 4: Pharmacoeconomics/Health Outcomes Funding
• Figure 4.7: Company 4: Outsourcing
• Figure 4.8: Company 4: Brand-Level Phase-to-Phase Minimum Spending
• Figure 4.9: Company 4: Brand-Level Phase-to-Phase Maximum Spending
• Figure 4.10: Company 4: Time Resource Allocation
• Figure 4.11: Company 4: Monetary Resource Allocation
• Figure 4.12: Company 4: Performance Rating

COMPANY 5

• Figure 5.1: Company 5: Background
• Figure 5.2: Company 5: Structure Details
• Figure 5.3: Company 5: Structure
• Figure 5.4: Company 5: Department Staffing
• Figure 5.5: Company 5: Pharmacoeconomics/Health Outcomes Funding
• Figure 5.6: Company 5: Brand-Level Pharmacoeconomics Spending
• Figure 5.7: Company 5: Monetary Resource Allocation
• Figure 5.8: Company 5: Time Resource Allocation
• Figure 5.9: Company 5: Outsourcing
• Figure 5.10: Company 5: Performance Rating/Top Challenges

COMPANY 6

• Figure 6.1: Company 6: Background
• Figure 6.2: Company 6: Structure Details
• Figure 6.3: Company 6: Department Structure
• Figure 6.4: Company 6: Department Staffing
• Figure 6.5: Company 6: Budget for 2006
• Figure 6.6: Company 6: Pharmacoeconomics/Health Outcomes Funding
• Figure 6.7: Company 6: Brand-Level Phase-to-Phase Minimum Spending
• Figure 6.8: Company 6: Brand-Level Phase-to-Phase Maximum Spending
• Figure 6.9: Company 6: Outsourcing
• Figure 6.10: Company 6: Time Resource Allocation
• Figure 6.11: Company 6: Monetary Resource Allocation
• Figure 6.12: Company 6: Performance Rating/Top Challenges

COMPANY 7

• Figure 7.1: Company 7: Background
• Figure 7.2: Company 7: Structure Details
• Figure 7.3: Company 7: Department Staffing
• Figure 7.4: Company 7: Global Department Structure
• Figure 7.5: Company 7: Budget for 2006
• Figure 7.6: Company 7: Pharmacoeconomics/Health Outcomes Funding
• Figure 7.7: Company 7: Outsourcing
• Figure 7.8: Company 7: Brand-Level Phase-to-Phase Minimum Spending
• Figure 7.9: Company 7: Brand-Level Phase-to-Phase Maximum Spending
• Figure 7.10: Company 7: Time Resource Allocation
• Figure 7.11: Company 7: Performance Rating/Top Challenges

COMPANY 8

• Figure 8.1: Company 8: Background
• Figure 8.2: Company 8: Structure Details
• Figure 8.3: Company 8: Department Staffing
• Figure 8.4: Company 8: Global Department Structure
• Figure 8.5: Company 8: Budget for 2006
• Figure 8.6: Company 8: Pharmacoeconomics/Health Outcomes Funding
• Figure 8.7: Company 8: Outsourcing
• Figure 8.8: Company 8: Brand-Level Phase-to-Phase Minimum Spending
• Figure 8.9: Company 8: Brand-Level Phase-to-Phase Maximum Spending
• Figure 8.10: Company 8: Time Resource Allocation
• Figure 8.11: Company 8: Monetary Resource Allocation
• Figure 8.12: Company 8: Performance Rating/Top Challenges

CROSS-COMPANY MEASURES

• Figure 9.1: Pharmacoeconomics/Health Outcomes 2006 Department Budgets
• Figure 9.2: Pharmacoeconomics/Health Outcomes Funding

Budgets and Spending

• Figure 9.3: Preclinical Maximum/Minimum Brand-Level Spending
• Figure 9.4: Phase I Maximum/Minimum Brand-Level Spending
• Figure 9.5: Phase II Maximum/Minimum Brand-Level Spending
• Figure 9.6: Phase IIIa Maximum/Minimum Brand-Level Spending
• Figure 9.7: Phase IIIb (Submission) Maximum/Minimum Brand-Level Spending
• Figure 9.8: Phase IV Maximum/Minimum Brand-Level Spending
• Figure 9.9: Average Costs of Cost-Minimization Studies
• Figure 9.10: Average Costs of Cost Effectiveness Studies

Costs of Pharmacoeconomics Studies

• Figure 9.11: Average Costs of Cost-Benefit Analyses
• Figure 9.12: Average Costs of Cost-Utility Analyses
• Figure 9.13: Average Costs of Budget impact Studies

Outsourcing

• Figure 9.14: Percentage of Pharmacoeconomics/Health Outcomes Spend Outsourced
• Figure 9.15: Percentage of Pharmacoeconomics/Health Outcomes Studies Outsourced

Staff Compensation Levels

• Figure 9.16: Compensation for Pharmacoeconomics/Health Outcomes Department Heads
• Figure 9.17: Compensation for Pharmacoeconomics/Health Outcomes Department Management Tier 1
• Figure 9.18: Compensation for Pharmacoeconomics/Health Outcomes Department Management Tier 2
• Figure 9.19: Compensation for Pharmacoeconomics/Health Outcomes Department Line Workers
• Figure 9.20: Compensation increase given for 1 to 2 Years Experience
• Figure 9.21: Compensation increase given for 2 to 3 Years Experience
• Figure 9.22: Compensation increase given for 3 to 4 Years Experience
• Figure 9.23: Compensation increase given for 5+ Years Experience